#### **Submission ID#** 1091537

# **Reaction Injection Molding Scale-up of Hydralese<sup>TM</sup>** (PGSU) Rods for Controlled Drug Delivery

# Dennis Carney, BS; Stephanie Reed, PhD

# Secant Group, LLC Telford, PA

**CONTACT:** dennis.carney@secant.com


## PURPOSE

Secant Group is developing long-acting implantable and gastroretentive devices manufactured from Hydralese™ (PGSU) (poly(glycerol sebacate) urethane) for controlled drug release over a multi-month time period. Secant Group has developed a pilot scale system to scale up the production of Hydralese (PGSU) using reaction injection molding (RIM). Secant's RIM unit provides temperature control, vacuum degassing, dynamic mixing, and precise component ratio metering. In combination with a cGMP grade 316 stainless steel mold, 40mm-long by 3mm-diameter implantable rods can be produced by reaction injection molding at mild (<100 psi) pressure and mild (20-40°C) temperature.

# **OBJECTIVES**

- 1. Manufacture unloaded Hydralese (PGSU) implants by a reaction injection molding process, and
- 2. Characterize the morphology, chemical structure, and crosslinking density of Hydralese (PGSU) implants.

# **METHODS**




#### LABORATORY SCALE – DUAL BARREL SYRINGE METHOD



Hydralese (PGSU) devices and implants are currently fabricated at the laboratory bench scale by crosslinking drug-loaded poly(glycerol sebacate) (PGS) resin via polyol-isocyanate urethane chemistry using a dual barrel syringe (DBS). The DBS extrudes the drug-polyol blend and the isocyanate crosslinker through separate barrels, and the two material streams meet in a static mixing tip, after which the blended material is flowed into a mold for ambient curing.

However, batch sizes are limited to ~50g, material is subject to ambient temperature effects, and high viscosity materials can be difficult to extrude. Secant Group pursued the development of a Reaction Injection Molding (RIM) to overcome these limitations. The RIM unit provides tight material metering, highspeed mixing, temperature and pressure control, and repeatable processing.





PGSU implants were made by a reaction injection molding method. The polyol (A-side) was comprised of pre-polymer PGS resin and a tin catalyst. The isocyanate (B-side) was comprised of hexamethylene diisocyanate (HDI). The components were brought up to temperature (30°C each) and degassed with vacuum and a vertical auger shaft. Using a submerged gear pump, each material was pumped in recirculation through a pressure transducer and a gear flow meter until steady state pressure and flow was achieved. The programmable logic controller (PLC) of the RIM unit metered polyol and isocyanate components into a high-speed dynamic pin mixer at a ratio of 3.5:1 PGS:HDI w/w.

The mixture was injected at low-velocity laminar flow to reduce injection backpressure (<100 psi) and prevent demixing of the disparately viscous A/B material. To meet the low velocity flow limits of the high viscosity materials, mold runner design was simulated and optimized through computational fluid dynamics (CFD) analysis. The final design of the mold was machined from 316 stainless steel and included 100 mold cavities 40mm long by 3mm diameter, polished to cGMP grade surface finish (<0.8µm R<sub>a</sub>). Material was cured in the mold for 24 hours at 23°C before opening, ejecting material, and recovering product rods.

# RESULTS

#### Surface Finish Analysis by SEM





316SS Mold

3mm PE Tube Mold

SEM imaging of 3mm-diameter rod sample outer surface at 30x magnifications to compare surface finish of new 316 stainless steel mold and laboratory scale polyethylene tube molds. Note part line present on stainless steel mold rod.

# Pharm Sci 360

#### Mixing Uniformity and Crosslinking Density by FTIR

8mm x 40mm Polished (<0.8µm Ra)


Rod Cavities (x100)

Chemical structure was characterized by Fourier-transform infrared spectroscopy (FTIR). Crosslinking density of the rods was determined by a trained macro comparing characteristic FTIR peaks linearly related to PGS:HDI weight ratio. Heat map of rod samples is presented, demonstrating A-side (PGS) : B-side (HDI) mix uniformity. All rods fall within PGSU crosslink density specification of 3.4:1 to 3.6:1 PGS:HDI.

AIR VENTS (x10)

316SS Mold (Top Half)

USL	3.40
LSL	3.60
Mean	3.54
RSD	0.88%
Min	3.46
Max	3.60
Min	3.46




**PGSU Implant Rod** 

(3mm x 40mm) (Unloaded)



# CONCLUSIONS

- Reaction injection molding of Hydralese (PGSU) is an excellent commercial scale production process that allows for increased production volumes while maintaining control over product quality and finish.
- Results are comparable to current laboratory scale production methods.
- Precise metering of component ratios allows for repeatable production of low variability crosslink densities for controlled drug-release profiles.
- With strong process control and the capability to produce various shapes, sizes, and formulations of product at cGMP conditions, reaction injection molding of Hydralese (PGSU) is an exceptional choice for commercial scale production of drug-loaded long-acting implantable and gastroretentive devices.



Hydralese<sup>™</sup> Biodegradable Elastomers

### REFERENCES

- Reed, S., Smoot, C., Shull, D., Crumbling, T., D'Ottavio, J., Gabriele, P. D., Ely, J. "Tunable, controlled-release, urethane-containing elastomers and processes of forming the same" (2020). U.S. Patent Application No. 16/547,175.
- Nicholson, C. B., Harris, J. J., Gabriele, P. D. "Watermediated preparations of polymeric materials" (2016). U.S. Patent No. 9,359,472.





PARTNERS FROM INSPIRATION TO REALIZATION